非高密度脂蛋白胆固醇水平与周围动脉疾病的相关性研究

doi:10.3969/j.issn.1673-5765.2021.06.011

中国卒中杂志 ›› 2021, Vol. 16 ›› Issue (06): 590-595.DOI: 10.3969/j.issn.1673-5765.2021.06.011

非高密度脂蛋白胆固醇水平与周围动脉疾病的相关性研究

牛松涛, 王安心, 吴建维, 王玉, 赵性泉

1北京 100070首都医科大学附属北京天坛医院神经病学中心
2国家神经系统疾病临床医学研究中心
3中国医学科学院脑血管病人工智能研究创新单元

收稿日期:2021-02-21 出版日期:2021-06-20 发布日期:2021-06-20
通讯作者: 赵性泉 zxq@vip.163.com
基金资助:
中国医学科学院医学与健康科技创新工程项目（2019-I2M-5-029）
北京市科委医药协同科技创新研究专项（Z201100005620010）

Association between Non-high-density Lipoprotein Cholesterol Level and Peripheral Artery Disease

Received:2021-02-21 Online:2021-06-20 Published:2021-06-20

摘要/Abstract

摘要： 目的评估不同非高密度脂蛋白胆固醇（non-high-density lipoprotein cholesterol，non-HDL-C）水平与周围动脉疾病（peripheral artery disease，PAD）的关系。方法本研究纳入2010年6月-2011年6月年龄≥40岁、既往无心脑血管病史的社区人群，收集人口学信息、血管相关危险因素、生化相关检查等资料。PAD定义为踝臂指数＜0.9；non-HDL-C水平分为：正常＜4.1 mmol/L，边缘升高4.1～4.9 mmol/L，升高≥4.9 mmol/L；采用单因素和多因素logistic回归分析non-HDL-C水平与PAD的相关性。结果共纳入5132例受试者，平均年龄55.13±11.80岁，男性3214例（60.07%），平均non-HDL-C水平为3.42±1.00 mmol/L，其中PAD患病率为3.39%（174/5132）。PAD受试者non-HDL-C水平高于无PAD受试者，但差异无统计学意义（3.51±1.03 mmol/L vs 3.42±1.00 mmol/L，P＞0.05）。进一步多因素分析结果显示，边缘升高（OR 1.23，95%CI 0.78～1.93，P ＞0.05）和升高non-HDL-C水平（OR 1.24，95%CI 0.60～2.55，P＞0.05）与PAD患病风险无关。结论本研究中未发现non-HDL-C与PAD的相关性。

文章导读： 本研究未发现non-HDL-C水平与PAD风险的相关性，未来需要在更大规模的前瞻性队列研究中进一步验证non-HDL-C与PAD患病风险的关系。

关键词: 周围动脉疾病; 非高密度脂蛋白胆固醇; 低密度脂蛋白胆固醇

Abstract: Objective To investigate the association between non-high-density lipoprotein cholesterol (non- HDL-C) level and peripheral artery disease (PAD). Methods From June 2010 to June 2011, this study enrolled participants aged ≥40 years and without history of cardiovascular disease in a community-based program. Demographic information, vascular risk factors and laboratory test results were collected. Participants were diagnosed with PAD based on ankle-brachial index (ABI) <0.9. Multivariate logistic regression analysis was used to determine the association between non-HDL-C level and PAD. Results A total of 5132 eligible participants were included, with a mean age of 55.13±11.80 years, 3214 males (60.07%) and a mean non-HDL-C level of 3.42±1.00 mmol/L. Among them, the prevalence of PAD was 3.39% (174/5132). The level of non-HDL-C in participants with PAD was higher than that in those without PAD (3.51±1.03 mmol/L vs 3.42±1.00 mmol/L, P >0.05). Multivariate analysis showed that there was no association of the marginally-elevated (OR 1.23, 95%CI 0.78-1.93, P >0.05) and high non-HDL-C groups (OR 1.24, 95%CI 0.60-2.55, P >0.05) with PAD. Conclusions There was no association between non-HDL-C level and PAD.

Key words: Peripheral artery disease; Non-high-density lipoprotein cholesterol; Low-density lipoprotein cholesterol

牛松涛, 王安心, 吴建维, 王玉, 赵性泉. 非高密度脂蛋白胆固醇水平与周围动脉疾病的相关性研究[J]. 中国卒中杂志, 2021, 16(06): 590-595.

NIU Song-Tao, WANG An-Xin, WU Jian-Wei, WANG Yu, ZHAO Xing-Quan. Association between Non-high-density Lipoprotein Cholesterol Level and Peripheral Artery Disease[J]. Chinese Journal of Stroke, 2021, 16(06): 590-595.

参考文献

[1] FOWKES F G，ABOYANS V，FOWKES F J，et al.
Peripheral artery disease：epidemiology and global
perspectives[J]. Nat Rev Cardiol，2017，14（3）：156-
170.
[2] ABOYANS V，RICCO J B，BARTELINK M，et al.
2017 ESC guidelines on the Diagnosis and Treatment
of Peripheral Arterial Diseases，in collaboration
with the European Society for Vascular Surgery
（ESVS）：document covering atherosclerotic disease
of extracranial carotid and vertebral，mesenteric，
renal，upper and lower extremity arteriesEndorsed
by：the European Stroke Organization（ESO）The
Task Force for the Diagnosis and Treatment of
Peripheral Arterial Diseases of the European Society
of Cardiology（ESC）and of the European Society
for Vascular Surgery（ESVS）[J]. Eur Heart J，2018，
39（9）：763-816.
[3] KUMBHANI D J，STEG P G，CANNON C P，et al.
Statin therapy and long-term adverse limb outcomes
in patients with peripheral artery disease：insights
from the REACH registry[J]. Eur Heart J，2014，35
（41）：2864-2872.
[4] JONES W S，BAUMGARTNER I，HIATT W R，et
al. Ticagrelor compared with clopidogrel in patients
with prior lower extremity revascularization for
peripheral artery disease[J]. Circulation，2017，135

（3）：241-250.

[5] BONACA M P，GUTIERREZ J A，CREAGER
M A，et al. Acute limb ischemia and outcomes
with vorapaxar in patients with peripheral artery
disease：results from the trial to assess the effects
of vorapaxar in preventing heart attack and stroke
in patients with atherosclerosis-thrombolysis in
myocardial infarction 50（TRA2°P-TIMI 50）[J].
Circulation，2016，133（10）：997-1005.
[6] WU J W，CHEN S Y，LIU L P，et al. Non-highdensity
lipoprotein cholesterol vs low-density
lipoprotein cholesterol as a risk factor for ischemic
stroke：a result from the Kailuan study[J]. Neurol
Res，2013，35（5）：505-511.
[7] MICHOS E D，MCEVOY J W，BLUMENTHAL
R S. Lipid management for the prevention of
atherosclerotic cardiovascular disease[J]. N Engl J
Med，2019，381（16）：1557-1567.
[8] WU J W，ZHANG Q，YANG H J，et al. Association
between non-high-density-lipoprotein-cholesterol
levels and the prevalence of asymptomatic
intracranial arterial stenosis[J/OL]. PLoS One，2013，
8（5）：e65229[2021-02-01]. https：//doi.org/10.1371/
journal.pone.0065229.
[9] 中国成人血脂异常防治指南修订联合委员会. 中国
成人血脂异常防治指南（2016年修订版）[J]. 中国循
环杂志，2016，31（10）：937-950.
[10] GREENLAND P，ABRAMS J，AURIGEMMA
G P，et al. Prevention conference V：beyond
secondary prevention：identifying the high-risk
patient for primary prevention：noninvasive tests
of atherosclerotic burden：Writing Group Ⅲ[J/OL].
Circulation，2000，101（1）：E16-22[2021-02-01].
https：//doi.org/10.1161/01.cir.101.1.e16.
[11] CEA-SORIANO L，FOWKES F，JOHANSSON
S，et al. Time trends in peripheral artery disease
incidence，prevalence and secondary preventive
therapy：a cohort study in The Health Improvement
Network in the UK[J/OL]. BMJ Open，2018，8
（1）：e018184[2021-02-01]. https：//doi.org/10.1136/
bmjopen-2017-018184.
[12] SELVIN E，ERLINGER T P. Prevalence of and
risk factors for peripheral arterial disease in the
United States：results from the National Health
and Nutrition Examination Survey，1999-2000[J].
Circulation，2004，110（6）：738-743.
[13] DING C C，CHEN Y，SHI Y M，et al. Association
between nontraditional lipid profiles and
peripheral arterial disease in Chinese adults with
hypertension[J]. Lipids Health Dis，2020，19（1）：
231.
[14] ADAY A W，LAWLER P R，COOK N R，et al.
Lipoprotein particle profiles，standard lipids，and
peripheral artery disease incidence[J]. Circulation，
2018，138（21）：2330-2341.
[15] 陶红，林江，陈立新，等. 不同水平的低密度脂蛋白
胆固醇人群的动脉弹性[J]. 中华生物医学工程杂志，
2010，16（3）：249-251.
[16] 尹朝霞，史作霞，许京娟，等. 2型糖尿病患者周围动
脉疾病危险因素分析[J]. 中国医师进修杂志，2009，
32（31）：9-12.
[17] 董强，张月兰，王福莉，等. 踝臂指数与心血管病危
险因素的关系[J]. 中国动脉硬化杂志，2009，17（1）：
66-68.

非高密度脂蛋白胆固醇水平与周围动脉疾病的相关性研究

Association between Non-high-density Lipoprotein Cholesterol Level and Peripheral Artery Disease

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 4

编辑推荐

Metrics

[1]	邓奇乐, 吴介洪, 陈吉相. 前蛋白转化酶枯草溶菌素Kexin 9型抑制剂在缺血性卒中治疗中的研究进展[J]. 中国卒中杂志, 2021, 16(08): 850-854.
[2]	易立，杨伊姝，张婷婷，陈彬，汤劼. 正五聚蛋白3与缺血性卒中患者颈动脉狭窄的关系研究[J]. 中国卒中杂志, 2020, 15(05): 522-526.
[3]	中国卒中学会. 前蛋白转化酶枯草溶菌素Kexin 9型抑制剂在缺血性卒中二级预防中的临床应用专家共识[J]. 中国卒中杂志, 2019, 14(06): 594-599.
[4]	刘洋，郭阳. 非高密度脂蛋白胆固醇与心脑血管疾病关系研究进展[J]. 中国卒中杂志, 2015, 10(09): 799-803.